Tango Therapeutics, Inc. Operating Lease, Right-of-Use Asset, Amortization Expense
Tango Therapeutics, Inc. (TNGX) reported Operating Lease, Right-of-Use Asset, Amortization Expense of $1.96 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Cash Flow › Operating Activities
us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense · last filed 2026-08-11
- Tango Therapeutics, Inc. operating lease, right-of-use asset, amortization expense for the quarter ending 2026-06-30 was $988.00K, a 2.95% decline year-over-year.
- Tango Therapeutics, Inc. operating lease, right-of-use asset, amortization expense for the quarter ending 2026-03-31 was $972.00K, a 3.95% decline year-over-year.
- Tango Therapeutics, Inc. operating lease, right-of-use asset, amortization expense for the quarter ending 2025-12-31 was $958.00K, a 0.42% increase year-over-year.
- Tango Therapeutics, Inc. operating lease, right-of-use asset, amortization expense for the quarter ending 2025-09-30 was $973.00K, a 3.40% increase year-over-year.
- Tango Therapeutics, Inc. operating lease, right-of-use asset, amortization expense for fiscal 2025 was $3.96M, a 5.77% increase from fiscal 2024.
- Tango Therapeutics, Inc. operating lease, right-of-use asset, amortization expense for fiscal 2024 was $3.75M, a 3.85% increase from fiscal 2023.
- Tango Therapeutics, Inc. operating lease, right-of-use asset, amortization expense for fiscal 2023 was $3.61M, a 49.01% increase from fiscal 2022.
- Tango Therapeutics, Inc. operating lease, right-of-use asset, amortization expense for fiscal 2022 was $2.42M, a 126.38% increase from fiscal 2021.
| Period end | Operating Lease, Right-of-Use Asset, Amortization Expense 3 month | Operating Lease, Right-of-Use Asset, Amortization Expense 6 month | Operating Lease, Right-of-Use Asset, Amortization Expense 9 month | Operating Lease, Right-of-Use Asset, Amortization Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $988.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $1.96M 10-Q · filed 2026-08-11 | $2.92M derived: sum of 3 quarters · filed 2026-08-11 | $3.89M derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | $972.00K 10-Q · filed 2026-05-13 | $1.93M derived: sum of 2 quarters · filed 2026-05-13 | $2.90M derived: sum of 3 quarters · filed 2026-05-13 | $3.92M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | $958.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $1.93M derived: sum of 2 quarters · filed 2026-03-05 | $2.95M derived: sum of 3 quarters · filed 2026-08-11 | $3.96M 10-K · filed 2026-03-05 |
| 2025-09-30 | $973.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $1.99M derived: sum of 2 quarters · filed 2026-08-11 | $3.00M 10-Q · filed 2025-11-04 | $3.96M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | $1.02M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $2.03M 10-Q · filed 2026-08-11 | $2.98M derived: sum of 3 quarters · filed 2026-08-11 | $3.92M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | $1.01M 10-Q · filed 2026-05-13 | $1.97M derived: sum of 2 quarters · filed 2026-05-13 | $2.91M derived: sum of 3 quarters · filed 2026-05-13 | $3.83M derived: sum of 4 quarters · filed 2026-05-13 |
| 2024-12-31 | $954.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $1.90M derived: sum of 2 quarters · filed 2026-03-05 | $2.82M derived: sum of 3 quarters · filed 2026-03-05 | $3.75M 10-K · filed 2026-03-05 |
| 2024-09-30 | $941.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $1.87M derived: sum of 2 quarters · filed 2025-11-04 | $2.79M 10-Q · filed 2025-11-04 | $3.71M derived: sum of 4 quarters · filed 2026-03-05 |
| 2024-06-30 | $925.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-05 | $1.85M 10-Q · filed 2025-08-05 | $2.76M derived: sum of 3 quarters · filed 2026-03-05 | $3.67M derived: sum of 4 quarters · filed 2026-03-05 |
| 2024-03-31 | $925.00K 10-Q · filed 2025-05-12 | $1.84M derived: sum of 2 quarters · filed 2026-03-05 | $2.75M derived: sum of 3 quarters · filed 2026-03-05 | $3.65M derived: sum of 4 quarters · filed 2026-03-05 |
| 2023-12-31 | $914.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $1.82M derived: sum of 2 quarters · filed 2026-03-05 | $2.73M derived: sum of 3 quarters · filed 2026-03-05 | $3.61M 10-K · filed 2026-03-05 |
| 2023-09-30 | $911.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | $1.81M derived: sum of 2 quarters · filed 2024-11-06 | $2.69M 10-Q · filed 2024-11-06 | $3.57M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-06-30 | $904.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-07 | $1.78M 10-Q · filed 2024-08-07 | $2.66M derived: sum of 3 quarters · filed 2025-02-27 | $3.47M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-03-31 | $877.00K 10-Q · filed 2024-05-08 | $1.76M derived: sum of 2 quarters · filed 2025-02-27 | $2.56M derived: sum of 3 quarters · filed 2025-02-27 | $2.94M derived: sum of 4 quarters · filed 2025-02-27 |
| 2022-12-31 | $882.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $1.69M derived: sum of 2 quarters · filed 2025-02-27 | $2.06M derived: sum of 3 quarters · filed 2025-02-27 | $2.42M 10-K · filed 2025-02-27 |
| 2022-09-30 | $803.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-08 | $1.18M derived: sum of 2 quarters · filed 2023-11-08 | $1.54M 10-Q · filed 2023-11-08 | $1.86M derived: sum of 4 quarters · filed 2023-11-08 |
| 2022-06-30 | $374.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-07 | $735.00K 10-Q · filed 2023-08-07 | $1.06M derived: sum of 3 quarters · filed 2023-08-07 | $1.31M derived: sum of 4 quarters · filed 2023-08-07 |
| 2022-03-31 | $361.00K 10-Q · filed 2023-05-09 | $682.00K derived: sum of 2 quarters · filed 2023-05-09 | $938.00K derived: sum of 3 quarters · filed 2023-05-09 | $1.19M derived: sum of 4 quarters · filed 2023-05-09 |
| 2021-12-31 | $321.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-27 | $577.00K derived: sum of 2 quarters · filed 2023-03-27 | $827.00K derived: sum of 3 quarters · filed 2023-03-27 | $1.07M 10-K · filed 2023-03-27 |
| 2021-09-30 | $256.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | $506.00K derived: sum of 2 quarters · filed 2022-11-10 | $748.00K 10-Q · filed 2022-11-10 | $984.00K derived: sum of 4 quarters · filed 2022-11-10 |
| 2021-06-30 | $250.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-10 | $492.00K 10-Q · filed 2022-08-10 | $728.00K derived: sum of 3 quarters · filed 2022-08-10 | |
| 2021-03-31 | $242.00K 10-Q · filed 2022-05-11 | $478.00K derived: sum of 2 quarters · filed 2022-05-11 | ||
| 2020-12-31 | $236.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-28 | $907.00K 10-K · filed 2022-03-28 | ||
| 2020-09-30 | $671.00K 10-Q · filed 2021-11-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Indivior Pharmaceuticals, Inc. (INDV) | $4.250B | 14.09 | |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |